BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT)...
Cancer
Kura Oncology to Report Second Quarter 2025 Financial Results
SAN DIEGO, July 31, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Plus Therapeutics Provides US Launch Update for its CNSide® Diagnostic
CNSide available for the state of Texas in August 2025 Initial commercial focus on NCI-Designated Cancer Centers and large private...
Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
New clinical Precision Medicine population data demonstrates up to 84.6 Weeks (19.5 Months) ‘time saved’ by early-start ADAS-Cog13 difference: −5.43...
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients
– Initial interim safety, tolerability, biomarker, and preliminary efficacy data expected in Q1 2026 –MIAMI, July 31, 2025 (GLOBE NEWSWIRE)...
INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025...
Trial Evaluating Blood Test for 10 Cancers Reaches Major Milestone
SOUTHAMPTON, England, July 30, 2025 /PRNewswire/ -- MODERNISED (NIHR207538), a multi-site UK clinical study has passed a key milestone: over 450...
GRAIL to Present at Canaccord Genuity 45th Annual Growth Conference
MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect...
Remote Patient Monitoring Market to Grow at a CAGR of 19.0% from 2025 to 2032 | SkyQuest Technology Consulting
The growing chronic condition across the globe is expected to propel market growth. With an increasing prevalence of chronic conditions...
OncoHost Named Top Precision Oncology Solution for 2025
BINYAMINA, Israel and CARY, N.C., July 30, 2025 /PRNewswire/ -- OncoHost, a leader in precision oncology leveraging proteomics and AI to...
Cortechs.ai Announce Next-Gen NeuroQuant® Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation
SAN DIEGO, July 30, 2025 /PRNewswire/ -- Cortechs.ai, a pioneer in AI-powered medical imaging solutions, is pleased to announce the immediate...
PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
NEW YORK, July 30, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating...
IDEXX Releases 2024 Corporate Responsibility Report, Highlighting Progress Against Its Goals
WESTBROOK, Maine, July 30, 2025 /PRNewswire/ -- IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today...
Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin
– New patent enhances market position in Europe HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX)...
IMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025...
Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference
NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical...
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T...
BioNexus Gene Lab Corp. and Fidelion Diagnostics Announce Landmark Alliance—Touted as a new “DeepSeek Moment” in Precision Oncology
KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- BioNexus Gene Lab Corp. (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company...
Immutep Quarterly Activities Report Q4 FY25
Media Release The pivotal TACTI-004 Phase III trial in first line non-small cell lung cancer (1L NSCLC) continues to build...
ORYZON Reports Financial Results and Corporate Update for Half-Year Ending June 30, 2025
Between December 2024 and July 2025, Oryzon secured financing totaling €52 M, approx. $61 M (€30.0 M from a capital...